Synact in media

July 2020

Cision Promoted: Emission teckningsoptioner ska driva två projekt genom fas II

Read more

June 2020

Aktiespararna: Intensiv höst med sikte på utlicensiering i horisonten

Read more

BIOSTOCK: SynAct närmar sig studiestart efter myndighetsgodkännande

Read more

May 2020

Redeye: Interview with CEO Jeppe Øvlesen and CSO Thomas Jonassen (video call)

Read more

BIOSTOCK: SynAct comments on positive Phase II data

Read more

BIOSTOCK: SynAct kommenterar positiva fas II-data (in Swedish)

Read more

April 2020

BIOSTOCK: Synact Pharma on expansion into Covid-19

Read more

BIOSTOCK: SynAct Pharma om Covid-19-satsningen (in Swedish)

Read more

Synact Pharma in spotlightanalysen (in Swedish)

Read more

Medwatch: Synact rekrutterer fortsat til forsøg trods pandemi (in Danish)

Read more

March 2020

Dagens Industri: Spotlight-bolag planerar preparattester på coronapatienter (in Swedish)

Read more

Medwatch: Synact Pharma vil teste hovedkandidat som tillægsbehandling til coronasyge patienter (in Danish)

Read more

Life Science Sweden: Vill dämpa lunginflammationen vid covid-19 (in Swedish)

Read more

December 2019

Medwatch: Synact Pharma kommer i mål med aktieemission – overtegnet med 295 pct (in Danish)

Read more

November 2019

Medwatch: Synact får grønt lys til forsøg i Sverige (in Danish)

Read more

October 2019

Medwatch: Biotekselskab vil starte nyt forsøg med hovedaktiv og udsteder aktier for millioner (in Danish)

Read more

June 2019

Medwatch: Biotekchef lander ny bestyrelsespost efter hjemtur til Danmark (in Danish)

Read more

April 2019

Medwatch: Synact ready for phase II with arthritis candidate: “An important milestone for the company”

Read more

Medwatch: Synact er klar til fase 2 med gigthåb: “En stor milepæl for selskabet” (in Danish)

Read more

February 2019

Medwatch: Synact skal rejse 14 mio kr til nyt forsøg med hovedkandidat (in Danish)

Read more

August 2018

Medwatch: Synact Pharmas hovedkandidat viser lovende takter mod sjælden nyresygdom (in Danish)

Read more

May 2018

Medwatch: Synact Pharma fordobler svensk kapitalrejsning (in Danish)

Read more